More about Stryker Corporation
Regulatory Filings for Stryker Corporation
Fundamentals for Stryker Corporation
Fraud, Delays, and High Fees—Gone: The Underrated Fintech Shift Reshaping U.S. Local Economies
From Rhode Island to Vermont: The Proficiency Gap That's Quietly Dividing New England's Workforce
Regional Airports Poised for Growth Amid Airline Shakeups
From Fuel Shock to Factory Revival: The Surprising Rise of Hyper-Local Supply Chains in the U.S.
Fundamentals for Stryker Corporation
Business Operations:
Sector: HealthcareIndustry: Medical Devices
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, ankle, and trauma and extremities surgeries; and Mako Shoulder, which expands the smart robotics suite of applications. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 61 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
Revenue projections:
Revenues for SYK are expected to drop compared to the previous year, which could be a cause for concern for investors. A decline in earnings may negatively impact the company's profitability, leading cautious investors to reconsider their positions, as it often signals challenges in overall financial health.
Financial Ratios:
| currentRatio | 1.893000 |
|---|---|
| forwardPE | 19.482445 |
| debtToEquity | 72.971000 |
| earningsGrowth | 0.559000 |
| revenueGrowth | 0.114000 |
| grossMargins | 0.650420 |
| operatingMargins | 0.272350 |
| trailingEps | 8.400000 |
| forwardEps | 16.744050 |
A current ratio of 1.893 for SYK implies that the company has ample liquidity to meet its short-term debts. SYK's cash reserves and current assets should easily cover these obligations, highlighting its financial stability and ability to manage short-term liabilities.
SYK's Forward PE ratio suggests the stock price is reasonable in relation to earnings. It's not overpriced, providing room for future growth, making the stock a potentially valuable investment for those seeking long-term gains.
Positive earnings and revenue growth for SYK suggest that the company is positioned for business expansion. The company's strong financial performance indicates sustained growth, as increasing sales and profits fuel its future success.
Positive gross and operating margins for SYK highlight the company's profitability. These metrics reflect SYK's efficiency in controlling costs while generating strong revenue from its core operations, signaling robust financial health.
With SYK's forward EPS higher than its trailing EPS, the company is expected to be more profitable in the current financial year. This signals confidence in SYK's growth potential, as improved earnings are forecasted compared to the prior year's performance.
Price projections:
Throughout its recent performance, SYK's price has been consistently close to the lower range of projected values. This suggests that the company may face challenges in achieving higher valuations in the eyes of investors.
Insider Transactions:
SYK experienced 11 sell transactions with market price of 374.17909102006394 per share.No sell transactions were completed during the period under review.The recent buying activity at current Stryker Corporation price levels exceeds selling, suggesting a potential positive outlook. Investors may see this trend as an indicator that the stock is likely to perform well, reflecting growing confidence.
Recommendation changes over time:
Recent analysis shows a strong buy bias for Stryker Corporation, encouraging investors to view it as a solid investment option. The positive sentiment surrounding Stryker Corporation suggests it could be an attractive place to allocate funds, motivating potential investors to consider the stock as a valuable part of their portfolio.
DISCLAIMER: We provide information and our musings based on events, but nothing on this site can be considered professional advice of any kind.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst technicals.
Latest Regulatory Filings for SP5
Companies with the best and the worst fundamentals.
AI Data Centers Transform Small-Town USA: Jobs, Taxes, and Tech Ecosystems Explode
The $919 Billion Warning: What the Wholesale Inventory Explosion Really Means for Main Street
How U.S. Cities Are Turning Data and Infrastructure into Billion-Dollar Opportunities